

PF-PTD-246

Phenytoin



Clinical Indication



Epanutin

Phenytoin is a primary anticonvulsant for prophylaxis and treatment of partial and generalised tonic-clonic seizures. It is particularly appropriate where once daily dosing is an advantage. Main indications for monitoring are:

- On initiating therapy
- During I.V. therapy in status epilepticus
- Unexpected deterioration in seizure control
- As an adjunct to the diagnosis of toxicity
- When interacting drugs are added or withdrawn
- In pregnancy

Drug Kinetics: Phenytoin is metabolised by the hepatic mixed-function oxidase system, which has a limited capacity and can become saturated at phenytoin concentrations within the target range. When levels are close to the saturation point a small increase in dose can result in a marked increase in serum concentration: this saturation point varies widely between patients.

Toxicity: Symptoms of neurotoxicity (nausea, vomiting, tremor, and ataxia) are increasingly frequent as levels exceed 20 mg/L.

Overdose: Following overdose and confirmation of toxicity there is not a case for continuous monitoring of levels to decide when to resume therapy. Phenytoin half-life is usually between 24 and 48 hours but due to the saturation kinetics, levels will gradually fall and then plummet i.e. half-life will be dependent on serum levels. Usually, phenytoin is stopped for 2 to 3 days and then the normal dose resumed. Serum levels should be monitored 7-10 days later after steady state has been obtained.

An information sheet is available from National Poisons Service (Toxbase).

Part of Profile / See Also

Request Form

Availability / Frequency of

Analysis

Turnaround Time

Patient Preparation

Sample Requirements

Specimen Type

Volume

Acceptable Containers

Combined Pathology manual Blood form or ICE request. Please state dosage on request form.

On request during routine hours. Laboratory must be contacted regarding urgent requests.

Same day

Steady state levels. This is 4-5 days following a change in dose.

Serum and plasma

2 ml



Yellow top (SST) tube



PF-PTD-246



Green top (lithium-heparin) tube



paediatric orange top (lithium-heparin)



paediatric green top (lithium-heparin)

Plain serum samples may also be used.

Reference Range & Units

Therapeutic range: 5 - 20 mg/L.

This range is indicative only, and some patients tolerate higher levels and require them to achieve effective control. Other patients are adequately controlled at lower concentrations and there is no need to use higher doses in such patients.

Phenytoin is over 90% protein-bound in healthy adults on monotherapy, but binding is substantially reduced in neonates, pregnancy, renal or hepatic disease. In such cases, effective or toxic free drug levels are obtained at lower total serum pheytoin levels.

To convert from µmol/L to mg/L multiply by 0.253

Interferences

Interpretation & Clinical

Decision Value (if applicable)

Critical phoning limit >25 mg/L

References

Beckman kit insert

Pathology Harmony Group, Clinical Biochemistry Outcomes, January 2011 (www. pathologyharmony.co.uk)

Test code

PHNY

Lab Handling

Analysed from primary tube and stored at 4°C.

Serum and plasma samples stable for 7 days at 2-8°C.